Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more

Conditions: Vaccine Response
Interventions: Atorvastatin, Quadrivalent seasonal influenza vaccine; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Sucrose, Galactooligosaccharide; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 60 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Influenza
Interventions: Influenza A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Baltimore, Maryland • Rochester, New York • Nashville, Tennessee

Conditions: Influenza
Interventions: Influenza virus vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo, HD quadrivalent influenza vaccine; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more

Conditions: Influenza
Interventions: Peramivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Influenza
Interventions: Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza, Renal Failure
Interventions: Not listed
Lead sponsor: Midwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza
Interventions: CAIV-T 10^7, CAIVT 10^5, Placebo, TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Pittsburgh, Pennsylvania

Conditions: Influenza A
Interventions: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,977 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more

Conditions: Influenza
Interventions: Fluzone® (Aventis Pasteur inactivated influenza vaccine); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 1,316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Influenza, COVID-19
Interventions: Provider communication training; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 24,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
Interventions: Peramivir+SOC, Placebo+SOC; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 60
States / cities: La Mesa, California • Long Beach, California • Modesto, California + 49 more

Conditions: Influenza
Interventions: Inactivated, Split-Virion Influenza Virus; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more

Conditions: Influenza
Interventions: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: Ad4-H5-Vtn; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza Immunization, Health Volunteers
Interventions: Trivalent Recombinant Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Influenza, Human
Interventions: D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 99 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions: Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo; Dietary Supplement
Lead sponsor: Quantec Ltd; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza A Subtype H7N7 Infection
Interventions: Monovalent Influenza Subvirion Vaccine, H7N7; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Systems Biological Assessment of Statin Effect on Vaccine Responses

Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

Patient-Centered Practical Vaccine Talk For Busy Clinicians

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Trial to Describe the Safety and Immunogenicity of Fluzone®

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Age and Response to Flu Vaccines

Immune Defense Protein Impact On Respiratory Immune Outcomes

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults